Australia's most trusted
source of pharma news
Friday, 06 March 2026
Posted 6 March 2026 AM
CSL Seqirus has signed its first international contract for its new Tullamarine Manufacturing Facility, announced while the country's Prime Minister is visiting Australia.
Canada signed up for Seqirus to rapidly manufacture and deliver 15 million doses of cell-based adjuvanted pandemic influenza vaccine if an influenza pandemic is declared by the World Health Organization.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.